Monthly Archives: April 2012

  • HDACi clinical trial starts in Turin

    Posted on 9th April 2012 by Caroline in Uncategorized.

    Repligen Corp. (NASDAQ:RGEN) in Waltham has enrolled (March 2012) its first patient in a Phase 1 clinical trial of RG2833 in adult patients with Friedreich’s ataxia (FA), see http://www.masshightech.com/stories/2012/03/12/daily57-Repligen-begins-clinical-trial-of-drug-for-Friedreichs-ataxia.html Repligen also reported it’s year-end financial results for 2011, according to two announcements this week. The RG2833 drug candidate is an oral class 1 histone deacetylase […]

    Continue Reading...
    Comments Off on HDACi clinical trial starts in Turin